Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 16/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059240 | 0.90 | TLR7 (0.56) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL18588114 | 0.87 | TLR7 (0.58) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL3864770 | 0.86 | TLR7 (0.52) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL3862340 | 0.85 | TLR7 (0.59) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL13937462 | 0.83 | TLR7 (0.56) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL5749342 | 0.83 | TLR7 (0.54) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL5748744 | 0.83 | TLR7 (0.48) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL5617026 | 0.82 | TLR7 (0.55) | TLR7POLBADORA2ALMNAHRH2 | |
| SCHEMBL3862412 | 0.82 | TLR7 (0.53) | TLR7POLBADORA2ALMNAHRH2 | |
| Hydrochloric Acid SCHEMBL3863570 | 0.82 | TLR7 (0.53) | TLR7POLBADORA2ALMNAHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157453-B2 | Urea substituted imidazoquinolines | 3M INNOVATION PROPERTIES COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1198232-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050131009-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-6897221-B2 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040167154-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-6780873-B2 | FOR INDUCING CYTOKINE BIOSYNTHESIS IN ANIMALS, AND IN THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-24 | — | — | US | disclosed |
| EP-1438958-A1 | Carbamate substituted imidazoquinolines | 3M Innovative Properties Company (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20040019048-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-20040014754-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-6573273-B1 | Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-03 | — | — | US | disclosed |
| US-6541485-B1 | Useful as immune response modifiers; they induce the biosynthesis of various cytokines and are used to treat viral diseases and neoplastic diseases. | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167154-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885POLB 3690/4885ADORA2A 2629/4885 |
| US-20040019048-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885POLB 3690/4885ADORA2A 2629/4885 |
| US-20040014754-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885POLB 3690/4885ADORA2A 2629/4885 |
| US-20050131009-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885POLB 3690/4885ADORA2A 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.